Literature DB >> 7056274

Kinetics of furosemide in children with chronic renal failure undergoing regular haemodialysis.

E Riva, E Fossali, A Bettinelli.   

Abstract

Furosemide was measured by gas-liquid chromatography in blood and dialysis fluid from 7 children with chronic renal failure, undergoing regular haemodialysis. It was administered chronically, in two or three daily doses (4.2-9.4mg/kg). Two children received 1 mg/kg intravenously for determination of the pharmacokinetics. The half-life was longer than in adults and in anephric patients on haemodialysis. Systemic and renal clearance were also much lower. Plasma protein binding in 2 out of 6 cases was reduced as compared to normal adults. The data do not suggest any need to modify the present dosage schedule despite the 4-5 fold increase in the half-life of furosemide. The contribution of haemodialysis to drug clearance was minimal, and accounted for less than 10% of the total clearance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7056274     DOI: 10.1007/bf00637617

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  [Optimal dosage of furosemide in patients treated with repeated dialysis].

Authors:  C Jacobs; E Singlas; H Lockmane; J P Tillement; P Simon; M Legrain
Journal:  J Urol Nephrol (Paris)       Date:  1975-09

2.  Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure.

Authors:  F Andreasen; P Jakobsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-07

3.  Pharmacokinetics of furosemide in advanced renal failure.

Authors:  C M Huang; A J Atkinson; M Levin; N W Levin; A Quintanilla
Journal:  Clin Pharmacol Ther       Date:  1974-10       Impact factor: 6.875

4.  Pharmacokinetics of orally administered furosemide.

Authors:  M R Kelly; R E Cutler; A W Forrey; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

5.  Pharmacokinetics of furosemide in normal subjects and functionally anephric patients.

Authors:  R E Cutler; A W Forrey; T G Christopher; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-06       Impact factor: 6.875

6.  [Protein binding and elimination half-life of furosemide in chronic hemodialysed patients].

Authors:  S Decourt; B Flouvat; A Goupil; M Domart; M Mezgani; P Aubert; A Baglin
Journal:  Therapie       Date:  1979 May-Jun       Impact factor: 2.070

7.  Pharmacokinetic disposition and protein binding of furosemide in newborn infants.

Authors:  J V Aranda; J Perez; D S Sitar; J Collinage; A Portuguez-Malavasi; B Duffy; C Dupont
Journal:  J Pediatr       Date:  1978-09       Impact factor: 4.406

8.  Pharmacokinetics of furosemide in anephric patients and in normal subjects.

Authors:  F Andreasen; H E Hansen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

9.  Placental transfer of furosemide.

Authors:  B Beermann; M Groschinsky-Grind; L Fåhraeus; B Lindström
Journal:  Clin Pharmacol Ther       Date:  1978-11       Impact factor: 6.875

10.  Furosemide kinetics in renal failure.

Authors:  W J Tilstone; A Fine
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

View more
  4 in total

1.  Furosemide disposition in patients on CAPD.

Authors:  U Martin; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 2.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

3.  Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.

Authors:  H Ogata; Y Kawatsu; Y Maruyama; K Machida; T Haga
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.

Authors:  M Hammarlund-Udenaes; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.